GET DAILY SIGNALSWhy Is Globus Medical (GMED) Stock Down -11.17% Today?
Key Takeaways
- GMED shares fell 11.17% to $72.34, down $9.10 from the prior session's close of $81.44.
- The decline was driven by a third-quarter revenue miss and a cut to full-year 2026 revenue guidance.
- An analyst downgrade from BMO Capital, which lowered the stock to Market Perform and cut its price target, amplified the selling pressure.
- The move was company-specific, with the stock falling even as broader indices traded higher.
- Traders are watching upcoming product launches, Nevro stabilization, and the 2027 growth trajectory for signs of a turnaround.
- Explore Price Targets, Earnings, and Forecast pages for deeper analysis of GMED.
- Discover actionable trading ideas powered by AI by exploring Trending AI Robots.
Opening Summary
Globus Medical, Inc. (GMED), a global musculoskeletal device maker focused on spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies such as surgical robotics and navigation, saw its shares plunge 11.17% on Thursday. The stock closed at $72.34, down from a prior-session close of $81.44. The selloff was triggered by the company's third-quarter 2026 results, released after Wednesday's close, which showed revenue falling short of Wall Street expectations and prompted management to lower its full-year revenue outlook. While adjusted earnings topped estimates, the weaker top line and reduced guidance dominated the market reaction.
Earnings Results and Guidance Cut
The primary catalyst behind the decline was a disappointing revenue picture. Globus Medical reported third-quarter worldwide net sales of $763.7 million, a 0.7% year-over-year decline that came in well below the roughly $792 million analysts had forecast. The shortfall reflected softer U.S. Spine growth, which slowed to about 2% amid delayed product launches and production issues, along with a 25.7% drop in sales from the acquired Nevro spinal cord stimulation business. International sales also fell 5.7%.
Management compounded investor concerns by cutting full-year 2026 revenue guidance to $3.09 billion, down from a prior range of $3.18 billion to $3.22 billion, citing timing delays around new product introductions and softer contributions from competitive recruiting. Adjusted earnings per share of $1.23 narrowly beat the $1.20 consensus, and the company reaffirmed its full-year adjusted EPS outlook of $4.95 to $5.05, but those positives were overshadowed by the top-line deterioration and the first revenue guidance reduction of the year.
Analyst Downgrades and Ratings Reactions
The earnings-driven move was reinforced by a wave of analyst commentary. BMO Capital downgraded GMED from Outperform to Market Perform and reduced its price target from $94 to $78, pointing to the revenue miss and deteriorating near-term growth prospects. Needham lowered its price target from $117 to $100 while maintaining a Buy rating, and BTIG reiterated a Neutral stance. Wells Fargo offered a partial counterpoint by raising its target to $100 and keeping an Overweight rating, but that did little to offset the broader bearish reaction. Recent insider selling, including a share sale by a company director just before the results, added to the negative sentiment.
Market Context and Trading Activity
The decline was distinctly company-specific. On the same day GMED fell, the S&P 500 and Nasdaq Composite advanced, and the medical device sector faced no broad macro headwind. The stock traded on heavy volume, reflecting intense selling pressure as investors repriced the shares following the guidance cut. The move pushed the stock toward its lowest levels in over a year and represented a sharp giveback of the roughly 9% gain the shares had posted on Wednesday. From a technical standpoint, the decline carried the stock below key short-term support levels, with the down gap signaling a breakdown in the recent rally.
What Comes Next for GMED
Looking ahead, investors will focus on whether Globus Medical can reaccelerate growth into 2027. Management pointed to a "stacked" launch cadence, including the SCRIPT patient-specific implant line, the XLIF prone lateral solution, the Maxxis Air retractor, and the EIQ pedicle fixation suite, as catalysts that could restore momentum. Stabilizing the Nevro business and converting strong enabling-technology demand into sustained revenue remain key watch items. The company also authorized an additional $500 million in share repurchases and posted record quarterly free cash flow of $225 million, underscoring a resilient margin and cash-flow profile. Risks include continued spine-market softness, execution around new product launches, and the potential for further pressure on the top line before any reacceleration materializes.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to evaluate. Explore the page to see which AI-driven strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GMED in upward trend: 10-day moving average broke above 50-day moving average on October 26, 2026
The 10-day moving average for GMED crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 203 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
GMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 110 of 213 cases where GMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The 10-day RSI Indicator for GMED moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 23 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 62 cases where GMED's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMED as a result. In 52 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for GMED turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 32 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
GMED moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.293) is normal, around the industry mean (4.137). P/E Ratio (20.514) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of spinal implants
Industry MedicalNursingServices
Advertisement